WOVEN-PLANET-HOLDINGS
Nissin Food Products Co., Ltd. (Nissin Foods) and Toyota Motor Corporation (Toyota) have initiated an agreement to jointly foster human well-being through healthy eating. This proposed plan will explore using Nissin’s innovative food offering, based on the latest molecular nutritional science, to provide personalized, delicious, and healthy “Complete Nutrition Meals” for Woven City. Woven City is being developed in Susono City, Shizuoka Prefecture on behalf of Toyota by Woven Planet, Inc. (Woven Planet), a Toyota subsidiary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005380/en/
Specifically, the following initiatives will be considered.
(1) A joint demonstration on expanding food choices for Woven City and improve residents’ health through the provision of "Complete Nutrition Meals”
(2) Connect data to provide "Complete Nutrition Meals" optimization based on each individual’s needs
Through Woven City, Toyota is aiming to transform itself into a mobility company and will conduct many demonstrations with various partners. With Woven City, Toyota is taking on the challenge of pursuing well-being for all and expanding the very definition of "mobility" to make it more human-centered. The word "mobility" includes not only getting from point A to point B, but also "moving" people's hearts.
Under the slogan "Beyond Instant Foods," Nissin Foods is taking on the challenge of creating a new food culture that goes beyond the value of instant foods. As one of these efforts, Nissin Foods has been researching "Complete Nutrition Meals" that provide all the necessary nutrients with controlled calories, salt, sugar, and fat, while maintaining the appearance and taste of the food. Applying the technology they have developed for instant noodles and other products, Nissin Foods is making various efforts to realize food for the future by utilizing proprietary and cutting-edge food production technology.
Nissin Foods' goal of "Beyond Instant Foods" and Toyota Woven City's goal of "broadening the scope of mobility" are essentially the same, even if the industries involved are different. These aspirations of both companies are in line with each other, and have led to this basic agreement. The two companies will work together to realize well-being through food by offering Nissin Foods' "Complete Nutrition Meals" in Woven City, aiming for delicious and healthy products that are optimized for each individual’s needs.
“We strongly share Toyota's vision of ‘well-being for all’ and are very pleased to be a part of Woven City. This initiative is the first step toward realizing a ‘new diet’ that allows people to enjoy a ‘Complete Nutrition Meal’ optimized for each individual anytime, anywhere. We will continue to work on improving well-being through food by conducting medium to long-term demonstrations in Woven City based on the themes of ‘food and nutrition’ and ‘the correlation between food and the extension of healthy life expectancy.’ We will continue to take on further challenges to realize a world where people can enjoy whatever they want, whenever they want, and as much as they want, as never seen before, under the slogan "#Japan as a nation on the cutting edge of preventive medicine.”
Noritaka Ando, Executive Vice President & Representative Director, Chief Operating Officer of NISSIN FOODS HOLDINGS CO., LTD. and President & Representative Director of Nissin Food Products Co., Ltd.
“We are excited to partner with Nissin Foods, Japan’s leading food production company which is on an ongoing mission to create a new food culture beginning with the development of the world's first instant noodles. Through Woven City, Toyota strives to achieve well-being for all by conducting trials that will expand the meaning and value of ‘mobility’ and create healthy and satisfying eating experiences that ‘move’ people's hearts. While health requirements and eating preferences differ across individuals, within the living laboratory of Woven City, we will learn more about how custom diets inspire healthier lifestyles and greater happiness.
The problem of food waste and lack of access to affordable, healthy food is a global human rights issue. Toyota and Woven Planet believe that Toyota Production System principles that Toyota developed and implemented in Just-In-Time delivery of parts and supplies for manufacturing operations, have the potential to improve food supply chain operations, optimize freshness, and reduce food waste, if applied to food production and delivery.”
James Kuffner, Board of Directors Member and Chief Digital Officer of Toyota Motor Corporation and CEO of Woven Planet, Inc.
About Nissin Foods:
Nissin Food Products Co., Ltd. (Nissin Foods) history begins in 1958, from the invention of the world's first instant noodles, Chicken Ramen. Since then, Nissin Foods has continued to create new food cultures through the development of products such as the first cup-type instant noodles, Cup Noodles, and the world's first space food ramen, Space Ram. The instant noodles market has since been growing globally, now reaching an annual consumption of 100 billion servings. As a pioneer in creating new food cultures, Nissin Foods will continue to lead the global food scene through creativity and technology, under the slogan: "Beyond Instant Foods".
For more information, please visit https://www.nissin.com/en_jp/
About Toyota Motor Corporation
Toyota Motor Corporation (Toyota) (NYSE: TM) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 28 countries and regions, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries and regions under the brands Toyota, Lexus, Daihatsu and Hino.
For more information, please visit https://global.toyota/en
About Woven Planet
Woven Planet is building the safest mobility in the world. A subsidiary of Toyota, Woven Planet innovates and invests in new technologies, software, and business models that transform how we live, work and move. With a focus on automated driving, smart cities, robotics and more, Woven Planet builds on Toyota's legacy of trust to deliver secure, connected, reliable, and sustainable mobility solutions for all.
Learn more at https://www.woven-planet.global/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom